Suppr超能文献

食管外嗜酸性胃肠道疾病:一个不断发展的领域和命名法

Eosinophilic Gastrointestinal Diseases Beyond the Esophagus: An Evolving Field and Nomenclature.

作者信息

Redd Walker D, Dellon Evan S

机构信息

Center for Esophageal Diseases and Swallowing, Center for Gastrointestinal Biology and Disease, and Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

出版信息

Gastroenterol Hepatol (N Y). 2022 Sep;18(9):522-528.

Abstract

The eosinophilic gastrointestinal diseases (EGIDs) are a group of chronic, immune-mediated gastrointestinal (GI) diseases characterized by GI symptoms and pathologic eosinophilic infiltration of specific areas within the GI tract in the absence of secondary causes of eosinophilia. The non-eosinophilic esophagitis EGIDs remain understudied and likely underdiagnosed, owing in part to the lack of clarity in the terminology previously used to describe these diseases. The newly established EGID nomenclature framework includes a first-tier description of the specific location of GI tract involvement and a second-tier description with more granular characterizations of disease involvement. EGIDs can involve any segment or layer of the GI tract, so patients can present with a wide array of common, nonspecific GI symptoms. Diagnosing EGIDs requires endoscopic evaluation and biopsies showing increased eosinophilic tissue infiltration in the correct clinical context after ruling out other causes of eosinophilia. Although the pathogenesis is not yet fully understood, EGIDs are likely allergic conditions triggered by food antigen exposure. Most patients are currently treated with corticosteroids, but investigations of other pharmacologic and dietary therapies are ongoing. This article highlights the recently updated EGID nomenclature and summarizes the current understanding of the diagnosis, pathogenesis, and treatment of EGIDs.

摘要

嗜酸性粒细胞性胃肠道疾病(EGIDs)是一组慢性、免疫介导的胃肠道疾病,其特征为出现胃肠道症状,且胃肠道特定区域存在病理性嗜酸性粒细胞浸润,同时不存在嗜酸性粒细胞增多的继发原因。非嗜酸性粒细胞性食管炎的EGIDs研究较少,可能诊断不足,部分原因是此前用于描述这些疾病的术语不够清晰。新建立的EGID命名框架包括对胃肠道受累具体部位的一级描述以及对疾病受累情况更详细特征的二级描述。EGIDs可累及胃肠道的任何节段或层次,因此患者可能出现各种各样常见的非特异性胃肠道症状。诊断EGIDs需要进行内镜评估和活检,在排除嗜酸性粒细胞增多的其他原因后,在正确的临床背景下显示嗜酸性粒细胞组织浸润增加。虽然其发病机制尚未完全明确,但EGIDs可能是由食物抗原暴露引发的过敏性疾病。目前大多数患者接受皮质类固醇治疗,但对其他药物和饮食疗法的研究仍在进行中。本文重点介绍了最近更新的EGID命名,并总结了目前对EGIDs诊断、发病机制和治疗的认识。

相似文献

2
Eosinophilic Gastrointestinal Diseases in Childhood.
Ann Nutr Metab. 2018;73 Suppl 4:18-28. doi: 10.1159/000493668. Epub 2019 Feb 19.
3
Common and disparate clinical presentations and mechanisms in different eosinophilic gastrointestinal diseases.
J Allergy Clin Immunol. 2024 Jun;153(6):1472-1484. doi: 10.1016/j.jaci.2024.03.013. Epub 2024 Mar 28.
4
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature.
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2474-2484.e3. doi: 10.1016/j.cgh.2022.02.017. Epub 2022 Feb 16.
5
Eosinophilic Gastrointestinal Diseases in Children: A Practical Review.
Curr Pediatr Rev. 2020;16(2):106-114. doi: 10.2174/1573396315666191022154432.
6
Pharmacological treatment of eosinophilic gastrointestinal disorders.
Expert Rev Clin Pharmacol. 2016 Sep;9(9):1195-209. doi: 10.1080/17512433.2016.1190268. Epub 2016 Jun 6.
7
Eosinophil Involvement Outside the Esophagus in Eosinophilic Esophagitis.
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1531-1534.e2. doi: 10.1016/j.cgh.2023.12.004. Epub 2023 Dec 15.
8
Eosinophilic Disorders of the Gastrointestinal Tract and Associated Abdominal Viscera: Imaging Findings and Diagnosis.
Radiographics. 2022 Jul-Aug;42(4):1081-1102. doi: 10.1148/rg.220004. Epub 2022 Jun 24.
9
The pathology and causes of tissue eosinophilia in the gastrointestinal tract.
Histopathology. 2017 Aug;71(2):177-199. doi: 10.1111/his.13228. Epub 2017 May 26.
10
The role of the high-affinity IgE receptor, FcepsilonRI, in eosinophilic gastrointestinal diseases.
Immunol Allergy Clin North Am. 2009 Feb;29(1):159-70, xii. doi: 10.1016/j.iac.2008.09.004.

引用本文的文献

1
Remarkable increase in Interleukin-5 receptor expression beyond tissue eosinophils in inflammatory bowel disease.
Front Immunol. 2025 May 22;16:1589421. doi: 10.3389/fimmu.2025.1589421. eCollection 2025.
6
The Natural History of Eosinophilic Gastrointestinal Diseases Is Influenced by Age of Onset and Location of Involvement.
Am J Gastroenterol. 2024 Sep 1;119(9):1813-1820. doi: 10.14309/ajg.0000000000002869. Epub 2024 May 16.
7
Eosinophils in Oral Disease: A Narrative Review.
Int J Mol Sci. 2024 Apr 16;25(8):4373. doi: 10.3390/ijms25084373.
8
Eosinophilic gastritis in adult complicated by gastric ulcer perforation.
J Surg Case Rep. 2024 Mar 6;2024(3):rjae113. doi: 10.1093/jscr/rjae113. eCollection 2024 Mar.
9
Age-specific causes of upper gastrointestinal bleeding in children.
World J Gastroenterol. 2023 Dec 21;29(47):6095-6110. doi: 10.3748/wjg.v29.i47.6095.

本文引用的文献

1
Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1598-1605.e2. doi: 10.1016/j.jaip.2022.02.037. Epub 2022 Mar 10.
2
Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study.
Gastroenterology. 2022 May;162(6):1635-1649. doi: 10.1053/j.gastro.2022.01.022. Epub 2022 Jan 25.
3
Eosinophilic Gastrointestinal Diseases Beyond Eosinophilic Esophagitis.
Am J Gastroenterol. 2022 May 1;117(5):697-700. doi: 10.14309/ajg.0000000000001658. Epub 2022 Jan 25.
4
Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort.
Am J Gastroenterol. 2022 Mar 1;117(3):413-423. doi: 10.14309/ajg.0000000000001625.
5
Comparison of Nonesophageal Eosinophilic Gastrointestinal Disorders with Eosinophilic Esophagitis: A Nationwide Survey.
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3339-3349.e8. doi: 10.1016/j.jaip.2021.06.026. Epub 2021 Jun 29.
6
Peripheral eosinophilia and hypoalbuminemia are associated with a higher biopsy diagnostic yield for eosinophilic gastroenteritis.
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101746. doi: 10.1016/j.clinre.2021.101746. Epub 2021 Jun 25.
7
Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.
Clin Gastroenterol Hepatol. 2022 Mar;20(3):535-545.e15. doi: 10.1016/j.cgh.2021.05.053. Epub 2021 Jun 2.
8
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study.
J Allergy Clin Immunol Pract. 2021 May;9(5):2050-2059.e20. doi: 10.1016/j.jaip.2020.12.054. Epub 2021 Jan 10.
9
Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.
N Engl J Med. 2020 Oct 22;383(17):1624-1634. doi: 10.1056/NEJMoa2012047.
10
Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis.
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2102-2111. doi: 10.1016/j.cgh.2020.08.013. Epub 2020 Aug 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验